A Study to Evaluate Safety, Tolerability, and Efficacy Profile of Rivoceranib With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer
A Phase I/IIa Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of Rivoceranib in Combination With Paclitaxel in Advanced Gastric or Gastroesophageal Junction Cancer
Sponsor: Elevar Therapeutics
Terminated
Terminated after completion of Part 1 due to a change in research plan.
Other terminated trials from Elevar Therapeutics
- Adenoid Cystic Carcinoma · Phase PHASE2 · Jun 2023
- Metastatic Colorectal Cancer · Phase PHASE1 · May 2023
- Advanced Malignancies · Phase PHASE1 · Jul 2020
More terminations from Elevar Therapeutics
This PHASE1/PHASE2 trial investigates Gastric Cancer and Gastroesophageal Junction Adenocarcinoma and is currently terminated or withdrawn. Elevar Therapeutics leads this study, which shows 9 recorded versions since 2018 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
May 2022 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
Status: Recruiting → Terminated
-
Oct 2021 — May 2022 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 4 earlier versions
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
-
May 2019 — Mar 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Nov 2018 — May 2019 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Oct 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Elevar Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .